Conference Coverage with Social Media | Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Megan CoderExecutive Director atDigital Therapeutics Alliance

Real Time Coverage @BIOConvention #BIO2019: Machine Learning and Artificial Intelligence #AI: Realizing Precision Medicine One Patient at a Time

Posted in Artificial intelligence applications for cardiology, Artificial Intelligence in Medicine - Applications in Therapeutics, Big Data, Bioengineering & reverse engineering design, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Biological Networks, Conference Coverage with Social Media, Intelligent Information Systems, Uncategorized, tagged AI, Artificial intelligence, Big data, Machine Learning, Omics on June 5, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: Machine Learning and Artificial Intelligence: Realizing Precision Medicine One Patient at a Time

Reporter: Stephen J Williams, PhD @StephenJWillia2

Speakers

Andrea CoravosCEO/Co-founder atElektra Labs

Dr. Harietta EleftherochorinouPractice Leader, Global | Machine Learning & Artificial Intelligence Solutions, Real World & Analytics atIQVIA

Dr. Emmanuel FombuDirector, Digital Medicines and Innovation atNovartis

The impact of Machine Learning (ML) and Artificial Intelligence (AI) during the last decade has been tremendous. With the rise of infobesity, ML/AI is evolving to an essential capability to help mine the sheer volume of patient genomics, omics, sensor/wearables and real-world data, and unravel the knot of healthcare’s most complex questions.

Despite the advancements in technology, organizations struggle to prioritize and implement ML/AI to achieve the anticipated value, whilst managing the disruption that comes with it. In this session, panelists will discuss ML/AI implementation and adoption strategies that work. Panelists will draw upon their experiences as they share their success stories, discuss how to implement digital diagnostics, track disease progression and treatment, and increase commercial value and ROI compared against traditional approaches.

most of trials which are done are still in training AI/ML algorithms with training data sets. The best results however have been about 80% accuracy in training sets. Needs to improve
All data sets can be biased. For example a professor was looking at heartrate using a IR detector on a wearable but it wound up that different types of skin would generate a different signal to the detector so training sets maybe population biases (you are getting data from one group)
clinical grade equipment actually haven’t been trained on a large set like commercial versions of wearables, Commercial grade is tested on a larger study population. This can affect the AI/ML algorithms.
Regulations: The regulatory bodies responsible is up to debate. Whether FDA or FTC is responsible for AI/ML in healtcare and healthcare tech and IT is not fully decided yet. We don’t have the guidances for these new technologies
some rules: never use your own encryption always use industry standards especially when getting personal data from wearables. One hospital corrupted their system because their computer system was not up to date and could not protect against a virus transmitted by a wearable.
pharma companies understand they need to increase value of their products so very interested in how AI/ML can be used.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

# Hashtags

#BIO2019 (official meeting hashtag)

Posted in and Bioethics, Biotechnology, Conference Coverage with Social Media, CRISPR applied to Human Germ Line, CRISPR/Cas9 & Gene Editing, FDA, FDA Regulatory Affairs, FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning - GCP, GLP, ISO 14155, Gene Editing Impact on Longevity, Gene Therapy & Gene Editing Development, Health Law & Patient Safety, Health Law Policy, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, tagged biosafety and bioethics, CRISPR, CRISPR Biology • Genome Editing • Gene Drives • DNA Repair • Model and Industrial Organisms • Technology Development • Stem Cells/Cancer • Genome-Wide Screens, Duchenne muscular dystrophy, EMA, EUDRA, European Union, FDA, FDA 510(k) clearance, gene editing on June 5, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: Genome Editing and Regulatory Harmonization: Progress and Challenges

Real Time Coverage @BIOConvention #BIO2019: Genome Editing and Regulatory Harmonization: Progress and Challenges

Reporter: Stephen J Williams, PhD @StephenJWillia2

Genome editing offers the potential of new and effective treatments for genetic diseases. As companies work to develop these treatments, regulators are focused on ensuring that any such products meet applicable safety and efficacy requirements. This panel will discuss how European Union and United States regulators are approaching therapeutic use of genome editing, issues in harmonization between these two – and other – jurisdictions, challenges faced by industry as regulatory positions evolve, and steps that organizations and companies can take to facilitate approval and continued efforts at harmonization.

Speakers

Emily MardenCounsel Food Drug and Regulatory Life Sciences at Sidley Austin LLP

Gary CharbonneauSenior Vice President of Regulatory Affairs at Sarepta

Dr. Denise GavinActing Gene Therapy Branch Chief, Division of Cell and Gene Therapy at Center for Biologics Evaluation and Research (CBER), FDA

Georgia GavriilidouCounsel, Food, Drug and Medical Device Regulatory Life Sciences at Sidley Austin LLP

Daniel TakefmanSVP and Head of Regulatory Affairs at Spark Therapeutics

CBER: because of the nature of these gene therapies, which are mainly orphan, there is expedited review. Since they started this division in 2015, they have received over 1500 applications.

Spark: Most of the issues were issues with the primary disease not the gene therapy so they had to make new endpoint tests so had talks with FDA before they entered phase III. There has been great collaboration with FDA, now they partnered with Novartis to get approval outside US. You should be willing to partner with EU pharmas to expedite the regulatory process outside US. In China the process is new and Brazil is behind on their gene therapy guidance. However there is the new issue of repeat testing of your manufacturing process, as manufacturing of gene therapies had been small scale before. However he notes that problems with expedited review is tough because you don’t have alot of time to get data together. They were lucky that they had already done a randomized trial.

Sidley Austin: EU regulatory you make application with advance therapy you don’t have a national option, the regulation body assesses a committee to see if has applicability. Then it goes to a safety committee. EU has been quicker to approve these advance therapies. Twenty five percent of their applications are gene therapies. Companies having issues with manufacturing. There can be issues when the final application is formalized after discussions as problems may arise between discussions, preliminary applications, and final applications.

Sarepta: They have a robust gene therapy program. Their lead is a therapy for DMD (Duchenne’s Muscular Dystrophy) where affected males die by 25. Japan and EU have different regulatory applications and although they are similar and data can be transferred there is more paperwork required by EU. The US uses an IND for application. Global feedback is very challenging, they have had multiple meetings around the world and takes a long time preparing a briefing package….. putting a strain on the small biotechs. No company wants to be either just EU centric or US centric they just want to get out to market as fast as possible.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

# Hashtags

#BIO2019 (official meeting hashtag)

Sanjeev Wadhwa Chief Executive Officer at Life Singularity, Inc.

Real Time @BIOConvention #BIO2019:#Bitcoin Your Data! From Trusted Pharma Silos to Trustless Community-Owned Blockchain-Based Precision Medicine Data Trials

Posted in and Bioethics, Computational Biology/Systems and Bioinformatics, Conference Coverage with Social Media, Diagnostics and Lab Tests, Health Law & Patient Safety, HealthCare IT, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, tagged #mhealth, bitcoin, blockchain, Clinical Trials, healthIT on June 5, 2019| Leave a Comment »

Real Time @BIOConvention #BIO2019:#Bitcoin Your Data! From Trusted Pharma Silos to Trustless Community-Owned Blockchain-Based Precision Medicine Data Trials

Reporter: Stephen J Williams, PhD @StephenJWillia2

Speakers

James CanterburyPrincipal at EY

John KamaraFounder at Alpha Health

Dr. David KoepsellCEO at Encrypgen

Katherine KuzmeskasCEO at SimplyVitalHealth.com

Kamal ObbadCEO at Nebula Genomics

As care for lifestyle-driven chronic diseases expands in scope, prevention and recovery are becoming the new areas of focus. Building a precision medicine foundation that will promote ownership of individuals’ health data and allow for sharing and trading of this data could prove a great blockchain.

At its core, blockchain may offer the potential of a shared platform that decentralizes healthcare interactions ensuring access control, authenticity and integrity, while presenting the industry with radical possibilities for value-based care and reimbursement models. Panelists will explore these new discoveries as well as look to answer lingering questions, such as: are we off to a “trustless” information model underpinned by Bitcoin cryptocurrency, where no central authority validates the transactions in the ledger, and anyone whose computers can do the required math can join to mine and add blocks to your data? Would smart contracts begin to incentivize “rational” behaviors where consumers respond in a manner that makes their data interesting?

Moderator: Cybersecurity is extremely important in the minds of healthcare CEOs. CEO of Kaiser Permenente has listed this as one of main concerns for his company.

Sanjeey of Singularity: There are Very few companies in this space. Singularity have collected thousands of patient data. They wanted to do predictive health care, where a patient will know beforehand what health problems and issues to expect. Created a program called Virtual Assistant. As data is dynamic, the goal was to provide Virtual Assistant to everyone.

Benefits of blockchain: secure, simple to update, decentralized data; patient can control their own data, who sees it and monetize it.

Nebular Genetics: Company was founded by Dr. George Church, who had pioneered the next generation sequencing (NGS) methodology. The company goal is to make genomics available to all but this currently is not the case as NGS is not being used as frequently.

The problem is a data problem:

data not organized
data too parsed
data not accessible

Blockchain may be able to alleviate the accessibiltiy problem. Pharma is very interested in the data but expensive to collect. In addition many companies just do large scale but low depth sequencing. For example 23andme (which had recently made a big deal with Lilly for data) only sequences about 1% of genome.

There are two types of genome sequencing companies

large scale and low depth – like 23andme
smaller scale but higher depth – like DECODE and some of the EU EXOME sequencing efforts like the 1000 Project

Simply Vital Health: Harnesses blockchain to combat ineffeciencies in hospital records. They tackle the costs after acute care so increase the value based care. Most of healthcare is concentrated on the top earners and little is concentrated on the majority less affluent and poor. On addressing HIPAA compliance issues: they decided to work with HIPAA and comply but will wait for this industry to catch up so the industry as a whole can lobby to affect policy change required for blockchain technology to work efficiently in this arena. They will only work with known vendors: VERY Important to know where the data is kept and who are controlling the servers you are using. With other blockchain like Etherium or Bitcoin, the servers are anonymous.

Encrypgen: generates new blockchain for genomic data and NGS companies.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

# Hashtags

#BIO2019 (official meeting hashtag)

#blockchain

#bitcoin

#clinicaltrials

Real Time Coverage @BIOConvention #BIO2019: Keynote Address Jamie Dimon CEO @jpmorgan June 5 Philadelphia

Posted in Conference Coverage with Social Media, Ethics and Leadership, Executive Compensation - Big Pharma, Global Partnering & Biotech Investment, Income Geographic Distribution, Intellectual Property, International Global Work in Pharmaceutical, US and Global Economy: Trends and Findings, Venture Capital, tagged #JPM2019, Global Partnering & Biotech Investment, JP Morgan on June 5, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: Keynote Address Jamie Dimon CEO @jpmorgan June 5 Philadelphia

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Dr Janet Woodcock from FDA was given the BIO Heritage award for leading the FDA from safety focus of 90s to the Voice of the Patient. She became a champion for advocacy groups
Governor Phil Murphy, Governor of New Jersey, received the Governor of the Year Award. New Jersey known as medicine chest of the world, have first 3D printed drug on market and number two in biotech and number one on drug approvals. We must do more to foster stem education. It will take private and public capital investment. New Jersey matches federal dollars and had doubled the angel investor tax credit.
Dr. Kakkis CEO of Ultragenix wins the Genzyme Henri Termeer Award for visionary work. Dr. Termeer recently passed. Dr. Kakkis is awarded for work with patients of rare diseases and help formulating legislation to help patients with rare disease have access to investigational drugs quickly.
Dr. Jeremy Levin from OVID named new chair of BIO

Interview with Jamie Dimon, CEO of JPMorgan

Mr Dimon had recently survived throat cancer and now has a renewed dedication to improving people’s lives. With Amazon had embarked on a nonprofit experimental model to streamline healthcare for their employees. He said the hardest part of going through cancer was telling his parents and children.
On the bailout he said it was a lie all banks needed TARP but could not just give to some and not all. He says the financial system in US is very solid so next downturn will not come from financial sector and never is from geopolitical but trade issues could be a catalyst. Policy usually always does the opposite of what is intended. He announced no intention of running for President of US.
We need to keep a growth agenda which includes education and infrastructure, without these competitive business tax relief does no account for much. We need a better conversation of how government handles finances
Immigration, education very important. Higher education needs to reduce costs and incentivize the people they bring in to stay here.
on healthcare: JPM had reduced the deductables to zero for workers making $60,000 or less

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

# Hashtags

#BIO2019 (official meeting hashtag)

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 10, 2019: Deals and Announcements

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 8, 2019: Deals and Announcements

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: #JPM2019 for Jan. 8, 2019; Opening Videos, Novartis expands Cell Therapies, January 7 – 10, 2019, Westin St. Francis Hotel | San Francisco, California

SEEMA KUMARVice President, Innovation, Global Health and Policy Communication atJohnson & Johnson Innovation

Real Time Coverage @BIOConvention #BIO2019: Falling in Love with Science: Championing Science for Everyone, Everywhere

Posted in Conference Coverage with Social Media, Foundations for supporting Science and Education, Open Access Journals, Philanthropy to Academic Institution, Scientific & Biotech Conferences: Press Coverage, Scientific Publishing, Scientist: Career considerations, Women in Life Sciences, tagged #science2_0, science policy, science reporting, Scientific Publishing, women in computing, women in science, Young scientists on June 4, 2019| Leave a Comment »

Falling in Love with Science: Championing Science for Everyone, Everywhere June 4 2019

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Science and technology bring tremendous value to society in years of life and quality of life, yet the public often perceives science as difficult, irrelevant or even threatening. Moreover, the inspirational and moving stories of scientists and innovators working around the world are often hidden or misrepresented in popular culture. Whose responsibility is it to communicate science and engage the public in supporting the scientific enterprise? Can everyone be a Champion of Science and what are the solutions to enlist and engage more champions of science across generations and geographies? How do we work together to enhance transparency, accessibility and relevance of science for everyone, everywhere? Can science become more inclusive and engage hearts and not only minds?

Join this exciting session as Johnson & Johnson announces the winners of the Champions of Science – BioGENEius Storytelling Challenge, and brings together other key stakeholders in a discussion about the importance of engaging the public to fall in love in science all over again.

Sponsored by: Johnson & Johnson Innovation

Speakers

Nsikan AkpanDigital Science Producer, PBS News Hour atPBS Newshour

Arthur HorwichSterling Professor of Genetics and Professor of Pediatrics; Investigator HHMI atYale University

Siddhartha MukherjeeAssociate Professor, Medicine atColumbia University

Dr. Maria Luisa PinedaCEO & Co-Founder atEnvisagenics, Inc.

Emily WangSoftware Engineer, Facebook at2014 BioGENEius Challenge Winner

Seema: We need to solve the problem of the lack of trust in scientists. Some of JNJ winners of their acheivement program went on to become Nobel Laureates. Arthur Horwich and Hans Ullrich won the Jannsen Award for discovering compounds that could refold proteins, including protein chaperones. Many diseases occur because of protein misfolding like neuro-degenerative diseases.

Seema: Great science going on in Africa. JNJ wanted to showcase the great science in Africa. they awarded four individuals with storytelling award (Emily).

Dr. Horwich: got interested in science early on. Worked on N terminal mitochondrial signal peptides. also then got interested in how proteins fold and unfold and refold since the 1950s. He had changed the thinking of how proteins are processed within cells and over many years he had worked on this.

Emily Wang: Parents and schoolteachers prodded her curiosity in biology. The impact of day to day work of scientists is arduous but the little things can lead to advances that may help people. If passionate and have a great mentor then can get a foot in the door. Worked at Stanford in the lab.

Dr. Mukherjee: He likes to cure diseases, physican first, scientist second, writer third but he doesn’t separate this. In older times scientists wrote to think and true today. How we visualize the word, or use our hands, is similar. He takes the word translational research very seriously. Can you say in one sentence how this will help patients in three years?

There are multitude ways of love for science.

Dr. Pinela: loved asking big question and loved storytelling but asking bigger questions. Moved from Columbia and moved to US; loved the freedom and government funding situation at that time. Need the training and mentorship so mentors are a very big aspect in innovation as it led her to entrepreneurship. We need to use technology to disrupt and innovate.

Nsikin: A lot of mentors nurture curiosity. People like to see them in that story of curiosity. That is how is bases the PBS science videos: did a study on engagement and people wants a morality, and a science identity (an inner nerd in all of us i.e. spark the interest). The feedback if they focus on this has been positive.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

# Hashtags

#BIO2019 (official meeting hashtag)

Meir Pugatch Managing Director & Professor atPugatch Consilium; University of Maastricht

Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Foundations for supporting Science and Education, Pharmaceutical Drug Discovery, Scientific & Biotech Conferences: Press Coverage, Venture Capital, tagged #biotech, academic partnership, bioinvestment, Biotech Investment and Venture Growth: The Franchising of Intellectual Property as a Business Model, Global Partnering & Biotech Investment, Public–private partnership, Translational Research on June 4, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Reporter: Stephen J Williams PhD @StephenJWillia2

There is $200B in Global Investment in the Biopharmaceutical Sector Each Year. Who’s Getting It and Why?

115A, Level 100

Speakers

Dr. Woei-Jer ChuangDirector General, Department of Life Sciences atMinistry of Science and Technology, Taiwan

Ancizar Guerrero GilForeign Investment Executive Director in the United States atProcolombia

Park Jee MinDeputy Director of the Division of Health Industry Promotion atMinistry of Health and Welfare (MoHW)

Michael PergineAssociate Vice President, International Policy and Government Affairs atMerck & Co.

Prof. Peter PittsPresident and Co-Founder atCenter for Medicine in the Public Interest

Each country have their own needs and most important drug cost structure. Must involve patients and providers.

BCI survey: countries output different, who improved who didnt

Is industry having collaboration with government? hardly ten percent by survey and worse vice versa

Transparancy and holistic view important for collaboration

Korea: lack of communication need input from government on pricing; wants global open innovation and enhance RD investments

Tawain: price, price but based on efficacy; pharma needs to talk with doctors hospital patients, find balance

Pitts: we need trust; staff that country offices with people who know that country. Price not defining value

Columbia: need to attract investors

Navigating Translation: Leveraging Public Private Partnerships to Turn Academic Discoveries into Health

112AB, Level 100

Speakers

Dr. Kathleen RouscheProgram Director at National Institutes of Health/National Heart Lung and Blood Institute

Joseph PiconeProfessor, Department of Electrical and Computer Engineering at Temple University

Dr. Suguna RachakondaSenior Director, Product Development Global Cardiovascular Innovation Center and NCAI-CC at Cleveland Clinic

Dr. Jesus Soriano MollaProgram Director at National Science Foundation

Chris VlahosGlobal Head, Rare Disease External Innovation at Ipsen

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

# Hashtags

#BIO2019 (official meeting hashtag)

Julie Gerberding Executive Vice President & Chief Patient Officer at Merck & Co, Inc.

Real Time Coverage @BIOConvention #BIO2019: Understanding the Voices of Patients: Unique Perspectives on Healthcare; June 4

Posted in Conference Coverage with Social Media, Curation, Patents, Patient Experience, Patient-centered Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, Voices of Patients and Healthcare Providers, tagged Conference Coverage with Social Media, defining patient experience, drivers of patient experience, exceeding patient expectations, healthcare, voices of patients on June 4, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: Understanding the Voices of Patients: Unique Perspectives on Healthcare; June 4 11:00 AM

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Description

The role of the patient has evolved dramatically over the past decade. Not only are patients increasingly more involved in their healthcare decision making, they are also passionate advocates who work tirelessly to advance drug development research and development and secure a public policy environment that is patient-centric. Join a discussion with patient advocates as they discuss their journeys to diagnosis and their viewpoints on our healthcare system. They will share their perspectives on what it means to be a patient and how they are advocating in their own unique ways to achieve a common goal: bringing new treatments to patients.

Speakers

Christopher Anselmo Market Intelligence Manager atMuscular Dystrophy Association

Eve Bukowski Vice President, Patient Advocacy, Education & Outreach atCalifornia Life Sciences Association (CLSA)

Emily Kramer-Golinkoff Co-Founder atEmily’s Entourage

Christopher Anselmo: affected by MS but did not understand why he should be involved in a study at the time or share your story but he saw others who benefited from both of these and now is fervent patient advocate. Each patient is worth their weight in gold as needed for other patient support. The why needs to be asked of oneself before go out to other patients or into new trials. Might not see through to end if don’t have that discussion of why doing this.

Eve Bukowski: she had stomach aches, went to hospital, and diagnosed with constipation, but had stage III colon cancer. She was campaigning for Hillary Clinton but then started to campaign for her life. She wound up having multiple therapies and even many I/O trials. Fighting cancer is a mental challenge. She has been fighting for eleven years but has an amazing strength and will.

Emily Kramer: cystic fibrosis patient. Advocates for research as she has a mutant allele (nonsense mut) that is not targeted by the current new therapy against known mutants of CFTR. So started Emily’s Entourage for this orphan of an orphan disease. Funded $4 million in grants and helped develop a new startup and get early seed funding. Noticed that the infrastructure to get these drugs to market was broken and also is investing to shore up these breaks in drug pipeline infrastructure for orphan diseases. For progressive diseases she would like drug developers to shift the timelines or speed with which they get to take a chance and try that new possibility. As a patient advocacy org, they want to partner every step of the way with biotech/pharma, they understand co’s and stakeholders can only do so much but let’s break out of convention.

Julie: many patient advocacy groups go person to person and make a support network.

Please view our ebookVolume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

available on Amazon https://www.amazon.com/dp/B076HGB6MZ

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

# Hashtags

#BIO2019 (official meeting hashtag)

Real Time Coverage @BIOConvention #BIO2019: Keynote: Siddhartha Mukherjee, Oncologist and Pulitzer Author; June 4 9AM Philadelphia PA

Posted in Cancer - General, Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Conference Coverage with Social Media, interventional oncology, Interviews with Scientific Leaders, tagged #endcancer, @DrSidMukherjee, Columbia University Medical Center, Conference Coverage with Social Media, Immune-Oncology Drug Discovery, immunooncology, interviews with notable physician, interviews with notable scientist, scientific leaders on June 4, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: Keynote: Siddhartha Mukherjee, Oncologist and Pulitzer Author; June 4 9AM Philadelphia PA

Reporter: Stephen J. Williams, PhD. @StephenJWillia2

Article ID #268: Real Time Coverage @BIOConvention #BIO2019: Keynote: Siddhartha Mukherjee, Oncologist and Pulitzer Author; June 4 9AM Philadelphia PA. Published on 6/4/2019

WordCloud Image Produced by Adam Tubman

Hematologist and oncologist Siddhartha Mukherjee was born in New Delhi, India. He holds a BS in biology from Stanford University, a DPhil in immunology from Oxford University (where he was a Rhodes Scholar), and an MD from Harvard Medical School. He completed his internal medicine residency and an oncology fellowship at Massachusetts General Hospital. Dr. Murkherjee is an assistant professor of medicine at Columbia University Medical Center. He lives in Manhattan with his wife, artist Sarah Sze, and their two daughters. His Pulitzer Prize-winning book, The Emperor of All Maladies: A Biography of Cancer, tells the story of cancer from its first description in an ancient Egyptian scroll to the gleaming laboratories of modern research institutions. A three-part documentary series based on the book, directed by Barak Goodman and executive produced by Ken Burns, debuts on PBS stations March 30 and continues on March 31 and April 1. The film interweaves a sweeping historical narrative with intimate stories about contemporary patients and an investigation into the latest scientific breakthroughs. He has also written the award winning book “The Gene: An Intimate History” and is Founder of Vor Biopharma, who had just published on their CD33 engineered hematopoetic stem cells as an immunooncology therapy VOR33.

Hon. James C. Greenwood- former Congressional representative and Founder CEO of BIO: moderator

Greenwood: Never have the threats from DC to innovation in the biotech field been so great. Focused on some great recent innovations and successes in gene therapy. Although the cost high, father of two LMR retinopathy patients said if his sons had to go through a lifetime of constant care it would cost much more than the gene therapy from Spark cost. Politicians need to realize that medicines that completely cure diseases are worth much more. They should meet in the middle with respect to developing a new payer model that will not hurt innovation.

Dr. Mukherjee: He go into oncology from a virology PhD because he liked to understand the human aspect

of disease. As an oncologist he gets to interact more closely with patients. The oncology horizon is always changing. He likened his view of oncology and cancer as a pyramid with prevention the base, then early detection then therapy at top.

We haven’t found preventable human carcinogens, none that is highly proven causal

This will be the next challenge for cancer researchers, to figure out why we can’t identify these preventable carcinogens.

Our affiliate Vor Biopharma, co-founded by @DrSidMukherjee, published the results of a preclinical study of VOR33 in @PNASNews. Read about Vor’s novel approach to treating #cancer via engineered hematopoietic stem cells: https://t.co/6zvt0lWYjO #immunotherapy

— PureTech (@PureTechH) May 29, 2019

The link to the PNAS paper on VOR33 can be found here: https://www.pnas.org/content/early/2019/05/23/1819992116

Please follow on Twitter using these @ handles and # hashtags

@Handles

# Hashtags

#BIO2019 (official meeting hashtag)

Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders at https://www.amazon.com/dp/B078313281 – electronic Table of Contents

Jennifer Doudna and NPR science correspondent Joe Palca, several interviews

Practicing Oncology: Medscape Editor-in-Chief Eric J. Topol, MD interviews Siddhartha Mukherjee, MD, PhD

Eric Topol interviews Al Gore on Genomics and Privacy

Dr. Mercola Interviews Dr. Saul About Beta-Blockers

Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders